ReviewAnnals of neurology2014
Neuroimaging biomarkers for Parkinson disease: facts and fantasy.
Review in Annals of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review.Medicine · 2017Pooled it
- Preservation of Extracellular and Tissue Dopamine During Tyrosine Hydroxylase Loss in Rat 6-OHDA Parkinson's Model: Selective Compensation Restricted to Substantia Nigra.International journal of molecular sciences · 2026Article
- Review
- Dopamine Signaling in Substantia Nigra and Its Impact on Locomotor Function-Not a New Concept, but Neglected Reality.International journal of molecular sciences · 2024Review
- How should we be using biomarkers in trials of disease modification in Parkinson's disease?Brain : a journal of neurology · 2023Article
- The Future of Functional Neuroimaging in Parkinsonism: Prove It!JAMA neurology · 2023Article
- Regional serotonin terminal density in aging human brain: A [Aging brain · 2023Article
- A tissue-fraction estimation-based segmentation method for quantitative dopamine transporter SPECT.Medical physics · 2022Article
- Striatal Acetylcholine-Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET-Informed Correlational Tractography.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.Molecular neurobiology · 2022Review
- Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.International journal of molecular sciences · 2021Review
- Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.JAMA neurology · 2021Review
- The impact of dopamine DEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020Article
- Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study.The Lancet. Digital health · 2019Article
- Multimodal dopaminergic and free-water imaging in Parkinson's disease.Parkinsonism & related disorders · 2019Article
- PET Imaging in Movement Disorders.Seminars in nuclear medicine · 2018Review
- Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.Movement disorders : official journal of the Movement Disorder Society · 2018Article
- MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.Molecular neurobiology · 2018Article
- Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this grand rounds, we focus on development, validation, and application of neuroimaging biomarkers for Parkinson disease (PD). We cover whether such biomarkers can be used to identify presymptomatic individuals (probably yes), provide a measure of PD severity (in a limited fashion, but frequently done poorly), investigate pathophysiology of parkinsonian disorders (yes, if done carefully), play a role in differential diagnosis of parkinsonism (not well), and investigate pathology underlying cognitive impairment (yes, in conjunction with postmortem data). Along the way, we clarify several issues about definitions of biomarkers and surrogate endpoints. The goal of this lecture is to provide a basis for interpreting current literature and newly proposed clinical tools in PD. In the end, one should be able to critically distinguish fact from fantasy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.